Meriofert Set

Human luteinising hormone; Human follicle‑stimulating hormone, the active ingredient in Meriofert Set, is a gonadotropin presented as a sterile injectable solution for intramuscular or subcutaneous use. It is used to treat infertility related to hypogonadotropic hypogonadism, to induce ovulation in women, and to stimulate spermatogenesis in men.

GNH USA supplies Meriofert Set as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality and regulatory compliance across markets.

Meriofert Set, a gonadotropin preparation, is employed in reproductive endocrinology to address hormone‑dependent infertility. - Infertility due to hypogonadotropic hypogonadism: restores LH and FSH activity to promote gamete production. - Induction of ovulation: stimulates follicular development to enable ovulation in women undergoing assisted reproduction. - Stimulation of spermatogenesis: enhances testicular testosterone and sperm production in men with deficient gonadotropin secretion.

Adverse reactions to Meriofert Set may vary in frequency and severity.

Common Side Effects: - Injection site pain or erythema. - Headache. - Nausea or mild abdominal discomfort. - Transient ovarian hyperstimulation (mild). - Mild fluid retention. - Transient increase in estradiol levels.

Serious or Rare Side Effects: - Severe ovarian hyperstimulation syndrome. - Multiple gestation pregnancy. - Allergic reaction or anaphylaxis. - Thromboembolic events. - Significant ovarian cyst formation. - Severe abdominal pain with ascites.

When using Meriofert Set, clinicians should observe several safety measures. - Pregnancy testing: confirm non‑pregnant status before initiating therapy. - Monitor ovarian response: use ultrasound to avoid excessive stimulation. - Assess hormone levels: measure LH, FSH and estradiol during treatment. - Risk of multiple gestation: counsel patients on the possibility of twins or higher order pregnancies. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Potential drug interactions with Meriofert Set require careful assessment.

Major Interactions (Avoid): - GnRH agonists: may blunt the therapeutic response if given concurrently. - Oral contraceptives: suppress endogenous gonadotropins, reducing efficacy. - High‑dose estrogen therapy: antagonizes gonadotropin action.

Moderate Interactions (Monitor Closely): - Thyroid hormone replacement: adjust dosing as thyroid status influences gonadotropin response. - Corticosteroids: may affect steroidogenesis pathways. - Anticoagulants: monitor for bleeding complications if ovarian hyperstimulation occurs.